The Importance of Integrated Service Offerings in Biopharma

Smaller biotechs have pivoted in recent years from selling products early in the development cycle to holding onto their assets. However, managing every stage of the development process is beyond the reach of many firms. In a recent Drug Discovery Online article, David K. Lyon, Ph.D, of Lonza explains why an integrated service provider can help smaller firms bring molecules from the drawing board to the clinic.

According to Lyon, “By partnering with an integrated provider like Lonza, with capabilities across the whole supply chain from drug substance through to drug product, everything will be handled by a single supplier. It is far more convenient, and much easier to control. It is faster. There are even regulatory benefits. As we use the same processes throughout, reporting is seamless, avoiding the complication of having to combine data from disparate sources.”

To learn more, click here.

(Source: Drug Discovery Online, May 24^th, 2022)